Pacific Edge Limited (PFGTF) has released an update.
Pacific Edge Limited reported a modest decrease in Q2 FY25 Cxbladder test volumes compared to the previous quarter, attributing the dip to uncertainties over Medicare coverage. Despite this, the company saw strong demand from Kaiser Permanente and increased test volumes in the Asia Pacific region, mitigating the overall impact. The company remains focused on strategic initiatives aimed at enhancing clinical practice and medical reimbursement policies, which are expected to contribute to future growth.
For further insights into PFGTF stock, check out TipRanks’ Stock Analysis page.
